Results of management of cervical lymph node metastases in differentiated thyroid carcinoma: Experience in an upper middle-income country. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Background The elimination of HBV covalently closed circular DNA (cccDNA) remains a critical hurdle for chronic hepatitis B (CHB) management. Objective In this investigation, we examined the efficacy ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Immuneering will present an analysis of circulating tumor DNA (ctDNA) from ≥64 patients with RAS-mutant solid tumors treated with atebimetinib, showing that acquired MAPK pathway alterations are ...
Melanoma remains the most aggressive and lethal form of skin cancer, characterized by a high mutational burden and complex signaling dysregulation. Over the ...
Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, ...
CNW/ - Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in ...
Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On track for expanded pancreatic cancer ...
NEW YORK – Verastem Oncology has laid out a new registrational development pathway for the KRAS G12D inhibitor VS-7375 in pancreatic, colorectal, and non-small cell lung cancer after feedback from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results